Science Applications Int'l (SAIC) Tops Q4 EPS by 13c

Science Applications Int'l (NYSE: SAIC) reported Q4 EPS of $0.74, $0.13 better than the analyst estimate of $0.61. Revenue for the quarter came in at $1.07 billion versus the consensus estimate of $1.08 billion.

Total cash flows provided by operating activities for the quarter were $108 million, an increase of $12 million from the comparable prior year quarter. The increase in operating cash was primarily due to cash flows provided by Scitor, partially offset by higher interest payments on incremental borrowings ($9 million) and a current quarter internal investment of working capital for the Assault Amphibious Vehicle contract ($9 million).

Total cash flows provided by operating activities for the year were $226 million, a decrease of $51 million from the prior year. The decrease in operating cash was primarily due to the timing of income tax payments in the prior year ($29 million), current year payments for acquisition and integration costs ($18 million), an internal investment of working capital in the current year for the Assault Amphibious Vehicle contract ($29 million), and higher interest payments in the current year as a result of additional borrowings ($19 million). These decreases were partially offset by cash provided from the operating activities of Scitor.

During the quarter, SAIC deployed $46 million of capital, consisting of $14 million in cash dividends and $32 million in plan share repurchases (approximately 0.7 million shares) under SAIC’s previously announced share repurchase program. For the year, share repurchases totaled $50 million (approximately 1.1 million shares) and total share repurchases since the inception of the program in 2013 have totaled $200 million (approximately 4.7 million shares).

For earnings history and earnings-related data on Science Applications Int'l (SAIC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Aspire Biopharma to acquire automotive supplier for $30 million